Entering text into the input field will update the search result below

Arch Therapeutics, Inc. (ARTH) Reports Directors, Leadership Appointments

Jul. 03, 2013 10:57 AM ET4 Comments
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Seeking Alpha Analyst Since 2008

QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with companies that have huge potential to succeed in the short and long-term future. QualityStocks provides investor relations services to publicly traded companies in exchange for compensation. The content we provide via Seeking Alpha may be part of our efforts to widen a client’s exposure. To read our full disclaimer, visit http://disclaimer.qualitystocks.net.

Arch Therapeutics, a life science company and developer of AC5™ for controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, has named Dr. Avtar Dhillon as board chair, Dr. Arthur Rosenthal as director, and Dr. Terrence W. Norchi as president and CEO.

Dr. Dhillon has experience in company building, financing, and licensing with large industry partners, has served as the chairman of ARTH's board of directors since April 2013, and has been on the board of directors of Arch Biosurgery, Inc. (ABS) since May 2011.

His previous employment includes the roles of president, chairman and CEO of Inovio Pharmaceuticals where he led the successful turnaround of the company through restructuring, acquisition of technology from several European and North American companies, and a merger with VGX Pharmaceuticals. Dr. Dhillon also led several successful financings for Inovio and concluded numerous licensing deals that included global giants Merck and Wyeth (now Pfizer).

Dr. Rosenthal was appointed a director of ARTH upon the completion of the company's previously announced merger, and had been the chairman of the board of ABS since April 2011. He has 40 years of experience in senior research and product development through executive roles for medical technology companies. He has also directed commercialization efforts for hundreds of novel medical products. Dr. Rosenthal was formerly chief scientific officer at Boston Scientific and vice president of Research and Development at Johnson and Johnson Medical Products, Inc.

Dr. Norchi, on April 23, 2013, began his role with ARTH as president, CEO, and a director. Dr. Norchi has also served as the president, CEO, and director of ABS since co-founding it in 2006. He previously served as a portfolio manager and pharmaceutical analyst at Putnam Investments; senior global biotech and international pharmaceutical equity analyst at Citigroup Asset Management; and a sell-side analyst covering non-U.S. pharmaceutical equities at Sanford C. Bernstein in New York City.

For more information, visit archtherapeutics.com

Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.